Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) generates a steady flow of news as a major participant in pharmaceutical distribution, medical products manufacturing and distribution, home-health services, and specialty healthcare support. This CAH news page aggregates company press releases and third-party coverage so readers can follow how Cardinal Health’s strategy, operations, and capital decisions evolve over time.
Recent news highlights include updates on financial performance and outlook, such as first-quarter fiscal 2026 results reported via Form 8-K and subsequent press releases, where Cardinal Health discussed revenue growth, segment profit trends, and revised non-GAAP earnings guidance. The company also issues announcements about upcoming earnings releases and webcasts, providing dates and times for quarterly and annual results discussions.
Cardinal Health’s news flow also covers strategic initiatives and acquisitions. For example, the company has reported on its plan and subsequent completion of the acquisition of Solaris Health, described as a leading urology management services organization that adds scale to The Specialty Alliance. Other updates discuss growth in Specialty revenues, expansion of MSO platforms, and the role of BioPharma Solutions and Sonexus™ Access and Patient Support in serving manufacturer partners and patients.
Operational and infrastructure developments are another key news theme. Cardinal Health has announced a new flagship Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis, Indiana, a Consumer Health Logistics Center in Ohio, and new and planned at-Home Solutions distribution centers in Texas and California, all emphasizing automation and technology to support distribution and logistics.
Investors and observers can also find capital markets and governance updates in Cardinal Health’s news, including public offerings of notes to fund acquisitions, quarterly dividend declarations approved by the Board of Directors, and information related to annual shareholder meetings. Bookmark this page to review Cardinal Health (CAH) news across earnings, acquisitions, infrastructure investments, and governance developments in one place.
Cardinal Health (NYSE:CAH) announced on April 1, 2026 an expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis. The company added a high-capacity production line to its DMF, quadrupled weekly output since late 2024, and plans further capacity increases in 2026 to support clinical and future commercial targeted alpha therapies.
The expanded supply has supported more than 15 clinical trials and aims to improve access for developers of therapies for prostate, neuroendocrine, breast, colon, melanoma, and lymphoma.
Cardinal Health (NYSE: CAH) will release third-quarter fiscal 2026 results on April 30, 2026 before the New York Stock Exchange opens. A webcast discussion begins at 8:30 a.m. Eastern. Slides and a replay will be available on the company Investor Relations page for 12 months; no access code is required.
Cardinal Health (NYSE: CAH) appointed Patricia A. Hemingway Hall as Chair of the Board, effective March 23, 2026, succeeding Gregory B. Kenny upon his retirement. Ms. Hemingway Hall has served on the board since 2013 and chaired the Governance and Sustainability Committee for nearly seven years.
The company said Ms. Hemingway Hall brings deep healthcare leadership as former CEO of Health Care Service Corporation. Cardinal Health reiterated confidence in its fiscal 2026 outlook and will release third quarter fiscal 2026 earnings on April 30.
Cardinal Health (NYSE: CAH) released its 2026 Biosimilars Report highlighting measured cost savings and high provider confidence in biosimilars across physician practices. The report cites $56 billion in U.S. savings since 2015 and projects up to $181 billion in future savings if market and policy conditions align.
Key metrics: 99% of surveyed providers feel comfortable explaining biosimilars, oncology biosimilars reach an average 81% market share within five years, and nearly 25 biosimilars are expected to receive FDA approval over the next two years.
Cardinal Health (NYSE: CAH) said its Board approved a quarterly dividend of $0.5107 per share, payable April 15, 2026 to shareholders of record at the close of business April 1, 2026. The dividend will be paid out of the company's capital surplus.
Cardinal Health (NYSE: CAH) reported Q2 FY2026 revenue of $65.6 billion (+19% Y/Y), GAAP operating earnings of $707 million (+29%) and GAAP diluted EPS of $1.97 (+19%). Non-GAAP operating earnings were $877 million (+38%) and non-GAAP EPS was $2.63 (+36%).
The company raised FY2026 non-GAAP EPS guidance to $10.15–$10.35, completed $750 million of share repurchases year-to-date, and reached its targeted leverage range.
Cardinal Health (NYSE:CAH) raised its fiscal 2026 non‑GAAP diluted EPS outlook to at least $10.00 (from $9.65–$9.85) and expects Specialty revenues >$50 billion in fiscal 2026, a 16% three‑year CAGR. Management cited strong execution across five segments and will provide more detail on the Feb 5, 2026 earnings call.
The company highlighted BioPharma Solutions' expected >30% revenue growth in fiscal 2026, Sonexus™ serving >1 million patients, successful contract transitions ahead of the Jan 1, 2026 Medicare Drug Price Negotiation changes, and the new ContinuCare™ Pathway program (Publix enrolled ~1,400 pharmacies; program covers >11,000 pharmacies).
Cardinal Health (NYSE: CAH) will report second-quarter fiscal 2026 results on February 5, 2026, prior to the opening of trading on the New York Stock Exchange. The company will host a webcast discussion beginning at 8:30 a.m. Eastern.
Investors can access the live webcast and slide presentation through Cardinal Health's Investor Relations page with no access code required. Presentation slides and a replay will remain available on the Investor Relations page for 12 months.
Cardinal Health (NYSE: CAH) announced a quarterly cash dividend of $0.5107 per share, declared from the company's capital surplus.
The dividend is payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026.
Cardinal Health (NYSE: CAH) completed its acquisition of Solaris Health on November 3, 2025, adding the country's leading urology MSO to its MSO platform.
Solaris Health brings more than 750 providers across 250+ practice locations in 14 states, expanding the Urology Alliance and increasing Cardinal Health's MSO reach to approximately 3,000 providers in 32 states.